XBiotech
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2005-01-01
- Employees
- 82
- Market Cap
- $198M
- Website
- http://www.xbiotech.com
- Introduction
XBiotech, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutic antibodies. Its product pipeline includes oncology, infectious diseases, dermatology and inflammatory disorders. The company was founded by John Simard on March 22, 2005 and is headquartered in Austin, TX.
Natrunix in Combination With Methotrexate for Rheumatoid Arthritis Treatment
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- XBiotech, Inc.
- Target Recruit Count
- 108
- Registration Number
- NCT06590090
Natrunix in HLA-B27 Positive Subjects With Axial Spondyloarthritis
- First Posted Date
- 2024-07-29
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- XBiotech, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT06526377
Natrunix or Placebo in Combination With Methotrexate in Rheumatoid Arthritis
- First Posted Date
- 2022-05-06
- Last Posted Date
- 2025-01-16
- Lead Sponsor
- XBiotech, Inc.
- Target Recruit Count
- 243
- Registration Number
- NCT05363891
- Locations
- 🇺🇸
Medvin Clinical Research, Tujunga, California, United States
🇺🇸Reliable Clinical Research, LLC, Hialeah, Florida, United States
🇺🇸Angels Clinical Research Institute, Miami, Florida, United States
Natrunix Versus Methotrexate in Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: Natrunix placebo with MTX (+folate)Drug: Natrunix with MTX placebo (+folate)
- First Posted Date
- 2022-05-06
- Last Posted Date
- 2022-05-06
- Lead Sponsor
- XBiotech, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT05363917
Natrunix Safety PK Study in Healthy Volunteers
- Conditions
- Pharmacokinetics
- Interventions
- Biological: PlaceboBiological: NatrunixTM
- First Posted Date
- 2021-10-29
- Last Posted Date
- 2022-02-24
- Lead Sponsor
- XBiotech, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT05099510
- Locations
- 🇺🇸
BioBehavioral Research of Austin, A Telemed2U Company, Austin, Texas, United States
Hutrukin to Analyze Safety and PK in Healthy Volunteers
- Conditions
- Pharmacokinetics
- Interventions
- Biological: HutrukinBiological: Placebo
- First Posted Date
- 2021-10-28
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- XBiotech, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT05098080
- Locations
- 🇺🇸
BioBehavioral Research of Austin, A Telemed2U Company, Austin, Texas, United States
XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer
- Conditions
- Pancreatic Cancer
- Interventions
- Biological: XB2001 or Placebo
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- XBiotech, Inc.
- Target Recruit Count
- 76
- Registration Number
- NCT04825288
- Locations
- 🇺🇸
Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
🇺🇸Community Cancer Trials of Utah, Ogden, Utah, United States
🇺🇸UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Safety & Efficacy of True Human Antibody, 514G3, in Staphylococcus Aureus Bacteremia Hospitalized Subjects.
- Conditions
- Staphylococcus Aureus Bacteremia
- Interventions
- Biological: 514G3 (2 mg/kg) plus standard IV antibiotic treatmentBiological: 514G3 (10 mg/kg) plus standard IV antibiotic treatmentBiological: 514G3 (40 mg/kg) plus standard IV antibiotic treatmentOther: Placebo plus standard IV antibiotic treatment
- First Posted Date
- 2015-02-06
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- XBiotech, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT02357966
- Locations
- 🇺🇸
XBiotech Investigative Site, Charlotte, North Carolina, United States